MedinCell SA · EURONEXT:MEDCL

MedinCell SA — Conference Presentation (June 2022)

4 slides from MedinCell SA's conference presentation, June 2022

1. Slide 1: Financial information

   Financial information Income from ordinary activities: : 8,3 M€ Operating expenses: 32,2 M€ (73% R&D)

2. Slide 2: Financial information

   Financial information Income from ordinary activities: 8,3 M€ Operating expenses: 32,2 M€ (73% R&D) Cash consumption from operations: 21,4 M€

3. Slide 3: Financial information

   Financial information Income from ordinary activities: 8,3 M€ Operating expenses: 32,2 M€ (73% R&D) Cash consumption from operations: 21,4 M€ Available Cash as of March 31, 2022: 24,6 M€ in cash + 2,6 M€ in non risky financial assets Estimated financial visibility until September 2023

4. Slide 4: Financial information

   Financial information Income from ordinary activities: 8,3 M€ Operating expenses: 32,2 M€ (73% R&D) Cash consumption from operations: 21,4 M€ Available Cash as of March 31, 2022: 24,6 M€ in cash + 2,6 M€ in non risky financial assets Estimated financial visibility until September 2023

Medincell — Conference Presentation (June 2022) on 6ix